303 related articles for article (PubMed ID: 26419961)
21. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.
Hembrough T; Liao WL; Hartley CP; Ma PC; Velcheti V; Lanigan C; Thyparambil S; An E; Monga M; Krizman D; Burrows J; Tafe LJ
Clin Chem; 2016 Jan; 62(1):252-61. PubMed ID: 26585927
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
[TBL] [Abstract][Full Text] [Related]
23. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract][Full Text] [Related]
24. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
Sasaki T; Koivunen J; Ogino A; Yanagita M; Nikiforow S; Zheng W; Lathan C; Marcoux JP; Du J; Okuda K; Capelletti M; Shimamura T; Ercan D; Stumpfova M; Xiao Y; Weremowicz S; Butaney M; Heon S; Wilner K; Christensen JG; Eck MJ; Wong KK; Lindeman N; Gray NS; Rodig SJ; Jänne PA
Cancer Res; 2011 Sep; 71(18):6051-60. PubMed ID: 21791641
[TBL] [Abstract][Full Text] [Related]
25. ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer.
Mota I; Patrucco E; Mastini C; Mahadevan NR; Thai TC; Bergaggio E; Cheong TC; Leonardi G; Karaca-Atabay E; Campisi M; Poggio T; Menotti M; Ambrogio C; Longo DL; Klaeger S; Keshishian H; Sztupinszki ZM; Szallasi Z; Keskin DB; Duke-Cohan JS; Reinhold B; Carr SA; Wu CJ; Moynihan KD; Irvine DJ; Barbie DA; Reinherz EL; Voena C; Awad MM; Blasco RB; Chiarle R
Nat Cancer; 2023 Jul; 4(7):1016-1035. PubMed ID: 37430060
[TBL] [Abstract][Full Text] [Related]
26. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
Sang J; Acquaviva J; Friedland JC; Smith DL; Sequeira M; Zhang C; Jiang Q; Xue L; Lovly CM; Jimenez JP; Shaw AT; Doebele RC; He S; Bates RC; Camidge DR; Morris SW; El-Hariry I; Proia DA
Cancer Discov; 2013 Apr; 3(4):430-43. PubMed ID: 23533265
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
[TBL] [Abstract][Full Text] [Related]
28. Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
Kim SJ; Kim S; Kim DW; Kim M; Keam B; Kim TM; Lee Y; Koh J; Jeon YK; Heo DS
Cancer Res Treat; 2019 Jul; 51(3):1231-1240. PubMed ID: 30653748
[TBL] [Abstract][Full Text] [Related]
29. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
[TBL] [Abstract][Full Text] [Related]
30. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
[TBL] [Abstract][Full Text] [Related]
31. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
[TBL] [Abstract][Full Text] [Related]
32. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
34. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
Casaluce F; Sgambato A; Maione P; Rossi A; Ferrara C; Napolitano A; Palazzolo G; Ciardiello F; Gridelli C
Target Oncol; 2013 Mar; 8(1):55-67. PubMed ID: 23325296
[TBL] [Abstract][Full Text] [Related]
35. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
36. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
37. ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.
Cabezón-Gutiérrez L; Khosravi-Shahi P; Diaz-Muñoz-de-la-Espada VM; Carrión-Galindo JR; Eraña-Tomás I; Castro-Otero M
Lung; 2012 Aug; 190(4):381-8. PubMed ID: 22584871
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Arbour KC; Riely GJ
Hematol Oncol Clin North Am; 2017 Feb; 31(1):101-111. PubMed ID: 27912826
[TBL] [Abstract][Full Text] [Related]
39. ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
[TBL] [Abstract][Full Text] [Related]
40. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
Toyokawa G; Seto T
Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
